🇺🇸 Haemophilus b Conjugate Vaccine in United States

49 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Foetal Exposure During Pregnancy — 10 reports (20.41%)
  2. No Adverse Event — 7 reports (14.29%)
  3. Pyrexia — 6 reports (12.24%)
  4. Seizure — 5 reports (10.2%)
  5. Exposure Via Breast Milk — 4 reports (8.16%)
  6. Incorrect Dose Administered — 4 reports (8.16%)
  7. Off Label Use — 4 reports (8.16%)
  8. Atrial Septal Defect — 3 reports (6.12%)
  9. Diarrhoea — 3 reports (6.12%)
  10. Drug Ineffective — 3 reports (6.12%)

Source database →

Haemophilus b Conjugate Vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Haemophilus b Conjugate Vaccine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Haemophilus b Conjugate Vaccine in United States?

Sanofi Pasteur, a Sanofi Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.